A new report by visiongain predicts that the Indian Pharmaceutical market will reach $102.98bn in 2026. This forecast and others appear in Indian Pharmaceutical Market Forecast 2016-2026: Future Prospects for Leading Companies in Generics, OTC, Originator Products and Biosimilars Propelled by Growth in Key Therapeutic Areas published in November 2015. Visiongain is a business information provider based in London, UK.

This report examines the current and future trends in the Indian pharmaceutical market. India has the second largest population in the world and with high levels of acute and chronic disease, it is already the third largest pharmaceutical market in the world by volume. The Indian market is characterised by extreme levels of generic penetration and hence some of the lowest drug prices in the world. The Indian pharmaceutical market has shown remarkable growth in recent years and there are no signs of this growth slowing down any time soon. Given that Indian companies play a major role in the supply of the world’s generic medicines and the domestic Indian market is set to become a world leading market in the next decade, understanding the Indian pharmaceutical market and the opportunities available is crucial for all those in fields related to the sector.

In this report, we examine in detail a number of key drug types in the Indian market, including generic drugs, OTC products, patented drugs and biosimilars. Also included in this report are the revenue forecasts in the following therapeutic areas: infectious disease, cardiovascular disease, gastro-intestinal disease, respiratory disease, pain relief / analgesics, diabetes, vitamins / minerals / nutrients, dermatology, central nervous system (CNS) and gynaecology. Using both primary and secondary research, forecasts have been built for both therapeutic areas and drug types, accompanied by qualitative analysis covering key economic points, commercial news, and analysis of strengths, weaknesses, opportunities and threats.
Also included is analysis of the current leading players in the Indian pharmaceutical market. These companies include Sun Pharmaceuticals, Abbott India, Cipla, Cadila Healthcare, GSK India, Pfizer India and Lupin Pharmaceuticals. Historical financial performance over 10 years is analysed, along with a breakdown of each company’s leading products and recent merger and acquisition information is included along with an analysis of news that may influence the course of the company.

Matteo Bianchi, a pharmaceutical and medical devices industry analyst in visiongain, said: “The Indian pharmaceutical market has a potential for growth that is matched by no other major economy in the world. As the Indian economy grows and the people become more prosperous, the prevalence of non-communicable diseases will increase. With the right amount of investment in healthcare infrastructure, the Indian market has the capability to become one of the top 3 pharmaceutical markets in the world.”
Indian Pharmaceutical Market Forecast 2016-2026: Future Prospects for Leading Companies in Generics, OTC, Originator Products and Biosimilars Propelled by Growth in Key Therapeutic Areas adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.